NeurologyLive's Mind Moments podcast featured groundbreaking discussions on updated MS diagnostic criteria, advances in Alzheimer's treatment, and developments in ALS therapeutics throughout 2024. The most popular episodes covered critical topics including the new McDonald criteria for MS diagnosis, emerging RNA therapeutics for Alzheimer's disease, and insights from the PHOENIX trial in ALS.
Amylyx reported positive topline data from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, showing improvement or stabilization across key disease measures.
Eisai presented Phase 1/2 data on E2814, an anti-tau drug, showing reduced levels of disease biomarkers in participants with mild to moderate genetic Alzheimer’s.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.